Close Menu

NEW YORK (GenomeWeb) – Amoy Diagnostics said today that the Chinese National Medical Products Administration (NMPA) has approved its BRCA1 and BRCA2 gene mutation detection kit.

The next-generation sequencing-based kit is designed for the qualitative detection of BRCA1 and BRCA2 mutations in patients with different cancer types including ovarian cancer and breast cancer, and is the first BRCA gene mutation detection product approved in China, AmoyDx said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
16
Sponsored by
ArcherDX

This webinar will discuss a next-generation sequencing approach for detecting genomic mutations in hematologic maglignancies.

Oct
03

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.